2. Search Result
Search Result
Pathways Recommended: Anti-infection
Results for "

RSV infections

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

1

Biochemical Assay Reagents

14

Inhibitory Antibodies

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99756
    Nirsevimab
    2 Publications Verification

    MEDI8897

    		 RSV Infection
    Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .
    Nirsevimab
  • HY-P9944
    Palivizumab
    3 Publications Verification

    MEDI 493

    		 RSV Infection Inflammation/Immunology Cancer
    Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice .
    Palivizumab
  • HY-W251428
    Phosphatidylglycerols (egg) sodium salt

    Egg PG

    		 Biochemical Assay Reagents Others
    Phosphatidylglycerols (PG) is a selective inhibitor targeting the TLR4 accessory protein CD14/MD-2 complex, inhibiting LPS or virus (such as RSV)-mediated inflammatory signaling pathways through competitive binding. Phosphatidylglycerols directly bind to viral particles to block infection, inhibit COX-2 expression to reduce the release of inflammatory factors (IL-6, IL-8), and improve oxidative stress by regulating mitochondrial membrane phospholipid remodeling. Phosphatidylglycerols can be taken orally or by inhalation and can be used in the study of chronic inflammatory diseases (such as atherosclerosis) and respiratory viral infections (such as RSV) .
    Phosphatidylglycerols (egg) sodium salt
  • HY-P99804
    Clesrovimab
    3 Publications Verification

    MK1654

    		 RSV Infection
    Clesrovimab (MK1654) is a humanized IgG1 monoclonal antibody targeting the respiratory syncytial virus (RSV) protein F. Clesrovimab binds to pre-fusion and post-fusion forms of RSV-A fusion protein with high affinity, with corresponding KD values of 71 pM and 480 pM, respectively. Clesrovimab is applicable for the research of RSV infection .
    Clesrovimab
  • HY-123475A
    Sisunatovir hydrochloride
    4 Publications Verification

    RV521 hydrochloride

    		 RSV Infection
    Sisunatovir (RV521) hydrochloride is a potent and orally active respiratory syncytial virus (RSV) inhibitor with IC50 values of 1.4, 1.0 nM for RSV A, RSV B, respectively. Sisunatovir hydrochloride inhibits RSV infection and reduces virus titers in the lungs of mice .
    Sisunatovir hydrochloride
  • HY-123475
    Sisunatovir
    4 Publications Verification

    RV521

    		 RSV Infection
    Sisunatovir (RV521) is a potent and orally active respiratory syncytial virus (RSV) inhibitor with IC50 values of 1.4, 1.0 nM for RSV A, RSV B, respectively. Sisunatovir inhibits RSV infection and reduces virus titers in the lungs of mice .
    Sisunatovir
  • HY-P99209
    Motavizumab

    MEDI-524

    		 RSV Infection
    Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research .
    Motavizumab
  • HY-P99586
    Suptavumab

    REGN2222

    		 RSV Infection
    Suptavumab (REGN2222) is a human monoclonal antibody. Suptavumab can bind and block a conserved epitope on RSV A and B subtypes. Suptavumab can be used for the research of RSV infection .
    Suptavumab
  • HY-P991492
    RSM-01

    		RSV Infection
    RSM-01 is a monoclonal antibody targeting site Ø of the pre-fusion F glycoprotein (Fusion glycoprotein F0) of respiratory syncytial virus (RSV). RSM-01 can be used in studies related to RSV infection .
    RSM-01
  • HY-115574
    RSV L-protein-IN-1

    		RSV Infection
    RSV L-protein-IN-1 (compound D) is a potent inhibitor of Respiratory syncytial virus (RSV) (EC50=0.021 μM). RSV L-protein-IN-1 inhibits Polymerase (IC50=0.089 μM)，and blocks RSV mRNA synthesis by inhibiting guanylation of viral transcripts. RSV L-protein-IN-1 shows moderate cytotoxicity (CC50=8.4 μM，HEp-2)，also exhibits activity and lowers virus titers in mouse models of RSV infection .
    RSV L-protein-IN-1
  • HY-109004
    Enzaplatovir

    BTA-C585

    		 RSV Infection
    Enzaplatovir (BTA-C585) is an orally bioavailable Inhibitor for respiratory syncytial virus (RSV) infection .
    Enzaplatovir
  • HY-P991690
    Glarivibart

    		RSV Infection
    Glarivibart is a humanized IgG1κ monoclonal antibody inhibitor targeting Respiratory syncytial virus (RSV) fusion F protein (RSV-F). Glarivibart has significant antiviral activity. Glarivibart can be used for RSV infections research .
    Glarivibart
  • HY-138956
    MAY0132

    		NF-κB RSV Infection
    MAY0132 is a potent and selective EPAC2 inhibitor with an IC50 of 0.4 μM. MAY0132 significantly inhibits replication of HMPV, AdV and RSV, reduces viral infection-induced cytokine/chemokine production, and inhibits NF-κB activation. MAY0132 has antiviral activity and can be used in the study of respiratory virus infection .
    MAY0132
  • HY-163773
    JNJ-7950

    		RSV Infection
    JNJ-7950 (compound 5c) exhibits antiviral activity against RSV with an EC50 value of 0.78 nM. JNJ-7950 can be used in the study of respiratory tract infections .
    JNJ-7950
  • HY-171983
    RSV-IN-13

    		RSV Infection
    RSV-IN-13 (compound 24) is a selective RSV fusion protein inhibitor with antiviral activity. RSV-IN-13 has an EC50 of 444.2 nM against RSV A2 strain and a CC90 of 23.7 μM in HepG2 cells. RSV-IN-13 can block the virus from entering host cells. RSV-IN-13 can be used to study RSV infection .
    RSV-IN-13
  • HY-178151
    CGR-50

    		RSV Infection
    CGR-50 is a potent RSV fusion glycoprotein (F protein) inhibitor (EC50 = 32.6 nM against RSV A2 in HEp-2 cells). CGR-50 blocks RSV entry by binding to the F protein and inhibiting membrane fusion. CGR-50 can be used for RSV infection research .
    CGR-50
  • HY-114721
    BTA-9881

    MEDI-564

    		 RSV Infection
    BTA-9881 (MEDI-564) is a RSV inhibitor, with an EC50: 48 nM, 59 nM and 160 nM for RSV A2, RSV Long, and RSV B1. BTA-9881 has favorable pharmacokinetics property .
    BTA-9881
  • HY-168616
    CL-A3-7

    		RSV IGF-1R Infection
    CL-A3-7 is a virus-cell fusion inhibitor targeting the RSV F protein. It exerts its effect by blocking the interaction between the virus and the host IGF1R, effectively inhibiting infections of both wild-type RSV and the K394R variant. It is applicable to anti-RSV drug development and resistance-related research .
    CL-A3-7
  • HY-P991495
    VIR-8190

    		RSV Infection
    VIR-8190 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. VIR-8190 can be used in respiratory syncytial virus (RSV) and metapneumovirus infections research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
    VIR-8190
  • HY-161877
    GS-7682

    		RSV Infection
    GS-7682 is an antiviral compound. GS-7682 has inhibitory activity against pneumoviruses and picornaviruses. GS-7682 can be used in the study of respiratory diseases such as asthma and chronic obstructive pulmonary disease .
    GS-7682
  • HY-N17236
    Forsyshiyanine A

    		β-glucuronidase Influenza Virus RSV Infection
    Foryshiyanine A is a triterpenoid alkaloid. Foryshiyanine A possesses anti-inflammatory activity, inhibiting the release of β-glucuronidase from rat polymorphonuclear leukocytes. Foryshiyanine A exhibits antiviral activity, with an EC50 of 4.5 μM against respiratory syncytial virus (RSV) and an IC50 of 7.3 μM against influenza A virus (H1N1). Foryshiyanine A reduces viral load by disrupting viral replication and entry. Foryshiyanine A may be used for the researches of inflammation and infection .
    Forsyshiyanine A
  • HY-108002
    A 33903

    		RSV Infection
    A 33903 is a respiratory syncytial virus (RSV) replication inhibitor. A 33903 can be used for the research of RSV-infection .
    A 33903
  • HY-130627
    RSV/IAV-IN-2

    		RSV Influenza Virus Infection
    RSV/IAV-IN-2 (compound 14c) is a potent and dual inhibitor of RSV/IAV. RSV/IAV-IN-2 has lesser cytotoxicity than the clinical agent, Ribavirin. RSV/IAV-IN-2 has the potential for the research of RSV and/or IAV infections .
    RSV/IAV-IN-2
  • HY-130626
    RSV/IAV-IN-1

    		RSV Influenza Virus Infection
    RSV/IAV-IN-1 (compound 14e) is a potent and dual inhibitor of RSV/IAV. RSV/IAV-IN-1 has lesser cytotoxicity than the clinical agent, Ribavirin. RSV/IAV-IN-1 has the potential for the research of RSV and/or IAV infections .
    RSV/IAV-IN-1
  • HY-163567
    RSV-IN-10

    		RSV Infection
    RSV-IN-10 (compound 6a) shows antiviral activity against RSV with the IC50 of 4 μM. RSV-IN-10 can be used for study of respiratory infection .
    RSV-IN-10
  • HY-163568
    RSV-IN-11

    		RSV Infection
    RSV-IN-11 (compound 10b) shows antiviral activity against RSV with the IC50 of 6.32 μM. RSV-IN-10 can be used for study of respiratory infection .
    RSV-IN-11
  • HY-154968
    RSV L-protein-IN-5

    		RSV Infection
    RSV L-protein-IN-5 (compound E) is a potent inhibitor of Respiratory syncytial virus (RSV) (EC50=0.1 μM). RSV L-protein-IN-5 inhibits Polymerase (IC50=0.66 μM)，and blocks RSV mRNA synthesis by inhibiting guanylation of viral transcripts. RSV L-protein-IN-5 shows moderate cytotoxicity (CC50=10.7 μM，HEp-2)，also exhibits activity and lowers virus titers in mouse models of RSV infection .
    RSV L-protein-IN-5
  • HY-109004A
    (S)-Enzaplatovir

    (S)-BTA-C585

    		 RSV Cancer
    (S)-Enzaplatovir ((S)-BTA-C585) is the S-enantiomer of Enzaplatovir. (S)-Enzaplatovir shows antiviral activities with an EC50 of 56 nM for respiratory syncytial viral (RSV) (patent WO2011094823A1 compound 77) .
    (S)-Enzaplatovir
  • HY-P991494
    IN-002

    		RSV Infection
    IN-002 is a human monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. IN-002 can be used in respiratory syncytial virus (RSV) infections research.
    IN-002
  • HY-P991499
    EVO-46120

    		RSV Infection
    EVO-46120 is a human monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. EVO-46120 can be used in respiratory syncytial virus (RSV) and metapneumovirus infections research.
    EVO-46120
  • HY-P992175
    ADI-14448

    		RSV Infection
    ADI-14448 is a RSV prefusion fusion glycoprotein inhibitor and HMPV fusion glycoprotein inhibitor, with a Kd of 3.8 × 10 -10 M for RSV preF. ADI-14448 binds to epitope III of RSV preF, thereby blocking viral infection. ADI-14448 neutralizes RSV subtype A and HMPV subtype A1. ADI-14448 can be used in studies related to respiratory syncytial virus infection and metapneumovirus infection .
    ADI-14448
  • HY-185215
    GS-646089

    		DNA/RNA Synthesis RSV Infection
    GS-646089 is a broad-spectrum antiviral nucleoside analog that exhibits significant inhibitory activity against respiratory syncytial virus (RSV), human metapneumovirus (hMPV), rhinovirus (enterovirus) and enteroviruses. The IC50 of GS-646089 targeting RNA-dependent RNA polymerase (RdRp) ranges from 43 to 46 nM. GS-646089 blocks viral replication by being converted into a triphosphate metabolite intracellularly, which competes with ATP for incorporation into nascent RNA strands and acts as an immediate chain terminator. GS-646089 is the parent compound of the double prodrug GS-7682 (HY-161877), and is used in studies of acute respiratory viral infections and infections caused by related pathogens .
    GS-646089
  • HY-12983B
    ALS-8112-TP

    		Drug Metabolite DNA/RNA Synthesis Infection
    ALS-8112-TP is the 5'-triphosphate metabolite of ALS-8112 (HY-12983). ALS-8112-TP is a potent, selective and competitive respiratory syncytial virus (RSV) RNA polymerase inhibitor, with selectivity against polymerases from host or viruses unrelated to RSV such as hepatitis C virus (HCV). ALS-8112-TP can be efficiently recognized by the recombinant RSV polymerase complex, causing chain termination of RNA synthesis. ALS-8112-TP can be used for RSV-infection research .
    ALS-8112-TP
  • HY-120660
    AZD4316

    		RSV Infection
    AZD-4316 is a respiratory syncytial virus (RSV) L protein inhibitor. AZD-4316 has an inhibitory effect on RSV A subtypes (such as strain A2) and can effectively block viral replication in the early stage of infection (the viral entry stage). AZD-4316 is inactive when administered 12-24 hours after infection. AZD-4316 can be used for the research of RSV infection .
    AZD4316
  • HY-182030
    RSV fusion protein IN-1

    		RSV Infection
    RSV fusion protein IN-1 is an orally active RSV pre-fusion F protein inhibitor with an IC50 of 0.10 nM against RSV. RSV fusion protein IN-1 forms stable hydrogen bonds and π-π stacking interactions with pre-fusion F protein to block viral fusion and entry. RSV fusion protein IN-1 suppresses RSV F protein expression in epithelial cells. RSV fusion protein IN-1 reduces viral burden in the lungs of RSV-infected murine models.RSV fusion protein IN-1 can be used for the research of respiratory syncytial virus (RSV) infection .
    RSV fusion protein IN-1
  • HY-P992301
    Anti-RSV F Antibody (R4.C6)

    		RSV Infection
    Anti-RSV F Antibody (R4.C6) is a monoclonal antibody against RSV F, with a Kd of 0.34 nM for the post-fusion RSV F trimer. Anti-RSV F Antibody (R4.C6) recognizes a unique neutralizing epitope spanning epitopes II and IV on both pre-fusion and post-fusion RSV F. Anti-RSV F Antibody (R4.C6) can be used in studies related to respiratory syncytial virus infection .
    Anti-RSV F Antibody (R4.C6)
  • HY-109004AR
    (S)-Enzaplatovir (Standard)

    (S)-BTA-C585 (Standard)

    		 Reference Standards RSV Cancer
    (S)-Enzaplatovir (Standard) is the analytical standard of (S)-Enzaplatovir (HY-109004A). This product is intended for research and analytical applications. (S)-Enzaplatovir ((S)-BTA-C585) is the S-enantiomer of Enzaplatovir. (S)-Enzaplatovir shows antiviral activities with an EC50 of 56 nM for respiratory syncytial viral (RSV) (patent WO2011094823A1 compound 77) .
    (S)-Enzaplatovir (Standard)
  • HY-P992423
    NIAID RSVF2-5

    		RSV Infection
    NIAID RSVF2-5 is a human monoclonal antibody fragment. NIAID RSVF2-5 binds to conserved, distinct conformational epitopes on RSV fusion glycoprotein, and shows activity against RSV subgroup A and B strains. NIAID RSVF2-5 reduces pulmonary and lung viral titers in RSV-infected rodents. NIAID RSVF2-5 can be used for the research of respiratory syncytial virus infection .
    NIAID RSVF2-5
  • HY-P992174
    ADI-14359

    		RSV Infection
    ADI-14359 is an antibody that binds to RSV postF, with a KD value of 387 nM, and exhibits non-neutralizing activity. ADI-14359 binds to antigenic site I on RSV postF through interactions of its conserved CDR H3 motif, germline-encoded IGKV1-39 light chain residues and heavy chain residues, where the light chain mediates preferential binding to postF by conflicting with the rearranged preF region. ADI-14359 can be used in studies related to respiratory syncytial virus (RSV) infection .
    ADI-14359
  • HY-109004R
    Enzaplatovir (Standard)

    BTA-C585 (Standard)

    		 Reference Standards RSV Infection
    Enzaplatovir (Standard) is the analytical standard of Enzaplatovir (HY-109004). This product is intended for research and analytical applications. Enzaplatovir (BTA-C585) is an orally bioavailable Inhibitor for respiratory syncytial virus (RSV) infection .
    Enzaplatovir (Standard)
  • HY-179634
    ASF-006 sodium

    		SARS-CoV HIV Enterovirus Angiotensin-converting Enzyme (ACE) RSV Filovirus Infection
    ASF-006 sodium, a tetrapodal tryptophan derivative, is a potent viral invasion inhibitor. ASF-006 sodium shows potent antiviral activity against different SARS-CoV-2 Omicron variants but not against the ancestral SARS-CoV.2 strain (Wuhan-Hu-1). ASF-006 sodium competitively inhibits receptor-binding domain (RBD)-ACE2 binding via an allosteric mechanism. ASF-006 sodium inhibits Omicron BA.1, Omicron XBB.1.5, respiratory syncytial virus (RSV) and Ebola virus infection with IC50s of 0.02 μM, 0.3 μM, 1.52 μM and 0.2 μM, respectively. ASF-006 sodium inhibits cell entry of both HIV and enterovirus A71[1].
    ASF-006 sodium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: